Abstract
PREVIEWEarly initiation of therapy to decelerate the decline in beta cell function and achieve low hemoglobin A1c levels is advantageous in patients with type 2 diabetes. In this first of two articles on treatment of type 2 diabetes, the authors share their experience in optimizing therapy and advocate fixed-dose oral combinations because of lower cost, improved efficacy, better compliance, and fewer side effects. The second article (on page 15) looks at the use of injection therapy when oral therapy is not enough.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
